Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model

Talazoparib, a potent PARP inhibitor, induces synthetic lethality in BRCA-deficient cancers making it an attractive candidate for ovarian cancer treatment. However, its potency lends itself to side effects associated more closely with traditional chemotherapeutics than other clinically approved PARP...

Descripción completa

Detalles Bibliográficos
Autores principales: Baldwin, Paige, Ohman, Anders W., Medina, Jamie E., McCarthy, Eric T., Dinulescu, Daniela M., Sridhar, Srinivas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524318/
https://www.ncbi.nlm.nih.gov/pubmed/31134152
http://dx.doi.org/10.3389/fonc.2019.00353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524318/
https://www.ncbi.nlm.nih.gov/pubmed/31134152
http://dx.doi.org/10.3389/fonc.2019.00353

Ejemplares similares